Skip to main content
. 2019 Oct 17;8(10):1268. doi: 10.3390/cells8101268

Figure 4.

Figure 4

PR-619 enhanced cisplatin-induced cytotoxicity in human UC cells. (A) T24 and (B) BFTC-905 were treated with PR-619 (7.5 μM), cisplatin (15 μM), or a combination for 24 h. Apoptotic cells were analyzed through FACS flow cytometry with propidium iodide and annexin V-FITC staining. (C,D) show the quantitative analyses of apoptosis presented as the means ± SD. Data are presented as means ± SD; * p < 0.05 compared with controls. All results shown are representative of at least three independent experiments. (E) T24 and (F) BFTC-905 cells were treated with PR-619 (7.5 μM), cisplatin (15 μM), or a combination for 24 h. Total cell lysates were analyzed for Bcl-2 using Western blot analysis. (G) T24 and (H) BFTC-905 were exposed to cisplatin in combination with PR-619 at a 2:1 ratio for 24 h. Cell viability was determined using MTT assays. The median-effect plot, dose-effect plot, and combination index (CI) plot of PR-619 in combination with cisplatin were presented. CI values of less than one, equal to one, and greater than one were defined as synergistic, additive, and antagonistic, respectively.